Abstract
The integrated in silico–in vitro–in vivo approaches have fostered the development of new treatment strategies for glioblastoma patients and improved diagnosis, establishing the bridge between biochemical research and clinical practice. These approaches have provided new insights on the identification of bioactive compounds and on the complex mechanisms underlying the interactions among glioblastoma cells, and the tumor microenvironment. This review focuses on the key advances pertaining to computational modeling in glioblastoma, including predictive data on drug permeability across the blood–brain barrier, tumor growth and treatment responses. Structure- and ligand-based methods have been widely adopted, enabling the study of dynamic and evolutionary aspects of glioblastoma. Their potential applications as predictive tools and the advantages over other well-known methodologies are outlined. Challenges regarding in silico approaches for predicting tumor properties are also discussed.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 . Glioblastoma multiforme: pathogenesis and treatment. Pharmacol. Ther. 152, 63–82 (2015).Crossref, Medline, CAS, Google Scholar
- 2 Biocomputing: numerical simulation of glioblastoma growth using diffusion tensor imaging. Phys. Med. Biol. 53(4), 879–893 (2008).Crossref, Medline, Google Scholar
- 3 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).Crossref, Medline, CAS, Google Scholar
- 4 CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway. Cancer Lett. 381(2), 391–403 (2016).Crossref, Medline, CAS, Google Scholar
- 5 Dealing with diversity in computational cancer modeling. Cancer Inform. 12, 115–124 (2013).Crossref, Medline, Google Scholar
- 6 . In silico modelling of treatment-induced tumour cell kill: developments and advances. Comput. Math. Methods Med. 2012, 960256 (2012).Medline, Google Scholar
- 7 MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997–1003 (2005).Crossref, Medline, CAS, Google Scholar
- 8 In silico modeling predicts drug sensitivity of patient-derived cancer cells. J. Transl. Med. 12, 128 (2014). •• Application of in silico model simulating glioblastoma multiforme cells to predict therapeutic responses in patients.Crossref, Medline, Google Scholar
- 9 In silico analysis of nuclei in glioblastoma using large-scale microscopy images improves prediction of treatment response. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2011, 87–90 (2011).Medline, Google Scholar
- 10 . Computational modeling of brain tumors: discrete, continuum or hybrid? SMNS 15(1), 381 (2008).Google Scholar
- 11 . Can we predict blood brain barrier permeability of ligands using computational approaches? Interdiscip. Sci. 5(2), 95–101 (2013).Crossref, Medline, CAS, Google Scholar
- 12 . Multiscale cancer modeling. Annu. Rev. Biomed. Eng. 13, 127–155 (2011). • Interesting review of the multiscale cancer modeling encompassing both mathematical and computational approaches.Crossref, Medline, CAS, Google Scholar
- 13 . Molecular docking and structure-based drug design strategies. Molecules 20(7), 13384–13421 (2015).Crossref, Medline, CAS, Google Scholar
- 14 . Optimal magnetic field for crossing super-para-magnetic nanoparticles through the brain blood barrier: a computational approach. Biosensors 6(2), 25 (2016). •• Molecular dynamic simulation as a valuable tool for predicting the behavior of nanoparticles along the passage through the blood–brain barrier.Crossref, Medline, Google Scholar
- 15 . Predict drug permeability to blood-brain-barrier from clinical phenotypes: drug side effects and drug indications. Bioinformatics 33(6), 901–908 (2016).Google Scholar
- 16 . In silico, in vitro and in vivo methods to analyse drug permeation across the blood-brain barrier: a critical review. OA Anaesthetics 1(2), 13 (2013). • Comprehensive review of the integrated in silico–in vitro–in vivo approaches for blood–brain barrier permeability studies.Crossref, Google Scholar
- 17 . Integrating structure-based and ligand-based approaches for computational drug design. Future Med. Chem. 3(6), 735–750 (2011).Link, CAS, Google Scholar
- 18 . New methodologies for ligand-based virtual screening. Curr. Pharm. Des. 11(9), 1189–1202 (2005).Crossref, Medline, CAS, Google Scholar
- 19 . A method to predict blood-brain barrier permeability of drug-like compounds using molecular dynamics simulations. Biophys. J. 107(3), 630–641 (2014).Crossref, Medline, CAS, Google Scholar
- 20 . Molecular determinants of blood-brain barrier permeation. Ther. Deliv. 6(8), 961–971 (2015).Link, CAS, Google Scholar
- 21 . Computing the blood brain barrier (BBB) diffusion coefficient: a molecular dynamics approach. J. Magn. Magn. Mater. 410, 187–197 (2016).Crossref, CAS, Google Scholar
- 22 . Brain drug targeting: a computational approach for overcoming blood-brain barrier. Drug Discov. Today 14(21–22), 1030–1036 (2009).Crossref, Medline, CAS, Google Scholar
- 23 . Predicting efflux ratios and blood-brain barrier penetration from chemical structure: combining passive permeability with active efflux by p-glycoprotein. ACS Chem. Neurosci. 4(2), 361–367 (2013).Crossref, Medline, CAS, Google Scholar
- 24 . Blood–brain barrier permeability mechanisms in view of quantitative structure–activity relationships (QSAR). J. Pharm. Biomed. Anal. 108, 29–37 (2015).Crossref, Medline, CAS, Google Scholar
- 25 . QSAR modeling of the blood–brain barrier permeability for diverse organic compounds. Pharm. Res. 25(8), 1902 (2008).Crossref, Medline, CAS, Google Scholar
- 26 . Predicting binding to p-glycoprotein by flexible receptor docking. PLoS Comput. Biol. 7(6), e1002083 (2011).Crossref, Medline, CAS, Google Scholar
- 27 . Molecular modeling and ligand docking for Solute Carrier (SLC) transporters. Curr. Top. Med. Chem. 13(7), 843–856 (2013).Crossref, Medline, CAS, Google Scholar
- 28 . In vitro blood-brain barrier models: current and perspective technologies. J. Pharm. Sci. 101(4), 1337–1354 (2012).Crossref, Medline, CAS, Google Scholar
- 29 . Permeability of the blood-brain barrier: molecular mechanism of transport of drugs and physiologically important compounds. J. Membr. Biol. 248(4), 651–669 (2015).Crossref, Medline, CAS, Google Scholar
- 30 . Opening of the blood-brain barrier tight junction due to shock wave induced bubble collapse: a molecular dynamics simulation study. ACS Chem. Neurosci. 6(8), 1296–1301 (2015).Crossref, Medline, CAS, Google Scholar
- 31 . Free-energy patterns in inclusion complexes: the relevance of non-included moieties in the stability constants. Phys. Chem. Chem. Phys. 19(7), 5209–5221 (2017).Crossref, Medline, CAS, Google Scholar
- 32 . Molecular simulation of nonfacilitated membrane permeation. Biochim. Biophys. Acta 1858(7 Pt B), 1672–1687 (2016).Crossref, Medline, CAS, Google Scholar
- 33 . Distribution and dynamics of adamantanes in a lipid bilayer. Biophys. J. 95(12), 5627–5636 (2008).Crossref, Medline, CAS, Google Scholar
- 34 . Predicting blood–brain barrier partitioning of organic molecules using membrane–interaction qsar analysis. Pharm. Res. 19(11), 1611–1621 (2002).Crossref, Medline, CAS, Google Scholar
- 35 . Similarities and differences of serotonin and its precursors in their interactions with model membranes studied by molecular dynamics simulation. J. Mol. Struct. 1045, 124–130 (2013).Crossref, CAS, Google Scholar
- 36 . Computational study of superparamagnetic nanocapsules crossing the blood-brain barrier: a robotics approach. Presented at: 2012 IEEE/RSJ International Conference on Intelligent Robots and Systems. Vilamoura, Portugal, 7–12 October 2012.Crossref, Google Scholar
- 37 . Following amphiphilic molecules on their way through lipid membranes: development of a kinetic model of passive permeation through the blood-brain barrier [PhD thesis]. University of Coimbra, Coimbra, Portugal (2014).Google Scholar
- 38 . In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme. Bioinformation 6(3), 100–106 (2011).Crossref, Medline, Google Scholar
- 39 . A novel strategy for mechanism based computational drug discovery. Biomark. Cancer 2, 35–42 (2010).Crossref, Medline, Google Scholar
- 40 . Mathematical modeling of human glioma growth based on brain topological structures: study of two clinical cases. PloS ONE 7(6), e39616 (2012).Crossref, Medline, CAS, Google Scholar
- 41 . The role of the tumor microenvironment in glioblastoma: a mathematical model. IEEE Trans. Biomed. Eng. 64(3), 519–527 (2016).Medline, Google Scholar
- 42 . Mathematical modelling of a brain tumour initiation and early development: a coupled model of glioblastoma growth, pre-existing vessel co-option, angiogenesis and blood perfusion. PloS ONE 11(3), e0150296 (2016).Crossref, Medline, Google Scholar
- 43 . Mathematical modelling of spatio-temporal glioma evolution. Theor. Biol. Med. Model. 10, 47 (2013).Crossref, Medline, Google Scholar
- 44 . Diffusive modelling of glioma evolution: a review. J. Biomed. Sci. Eng. 3, 501–508 (2010).Crossref, Google Scholar
- 45 . Critical parameters determining standard radiotherapy treatment outcome for glioblastoma multiforme: a computer simulation. Open Biomed. Eng. J. 2, 43–51 (2008).Crossref, Medline, CAS, Google Scholar
- 46 . Monte Carlo simulation of base and nucleotide excision repair of clustered DNA damage sites. I. Model properties and predicted trends. Radiat. Res. 164(2), 180–193 (2005).Crossref, Medline, CAS, Google Scholar
- 47 . Monte-Carlo model development for evaluation of current clinical target volume definition for heterogeneous and hypoxic glioblastoma. Phys. Med. Biol. 61(9), 3407–3426 (2016).Crossref, Medline, CAS, Google Scholar
- 48 . An optical therapeutic protocol to treat brain metastasis by mapping NIR activated drug release: a pilot study. Presented at: 2014 IEEE Nuclear Science Symposium and Medical Imaging Conference (Nss/Mic). WA, USA, 8–15 November 2014.Crossref, Google Scholar
- 49 . DNA damage induced in glioblastoma cells by I-131: a comparison between experimental data and Monte Carlo simulation. Cell J. 14(1), 25–30 (2012).Medline, Google Scholar
- 50 . Mathematical modeling of GBM treatment: assessing the contributions of radiation therapy and the extent of surgical resection. Int. J. Radiat. Oncol. Biol. Phys. 96(2), e79 (2016).Crossref, Google Scholar
- 51 . In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma. J. R. Soc. Interface 12(109), 20150388 (2015).Crossref, Medline, Google Scholar

